

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application

Listing of Claims:

1. (Original) A pharmaceutical composition for preventing, treating, or prophylaxis of arthrosis, comprising a substance having an activity in modulating signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.

2. (Original) The pharmaceutical composition of claim 1, wherein the substance has an activity in inhibiting proliferation of AILIM-expressing cells or in inhibiting production of a cytokine by AILIM-expressing cells.

3. (Currently Amended) The pharmaceutical composition of claim 1 ~~or 2~~, wherein the cytokine is interferon γ which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

4. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1 to 3~~ claim 1, wherein the arthrosis is rheumatoid arthritis.

5. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1 to 3~~ claim 1, wherein the arthrosis is osteoarthritis.

6. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1 to 5~~ claim 1, wherein the substance is a protein substance.

7. (Original) The pharmaceutical composition of claim 6, wherein the protein substance is selected from the group consisting of:

- a) an antibody which binds to AILIM or a portion thereof;
- b) a polypeptide comprising the whole or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising the whole or a portion of an extracellular region of AILIM and the whole or a portion of a constant region of immunoglobulin heavy chain; and
- d) a polypeptide which binds to AILIM.

8. (Currently Amended) The pharmaceutical composition of ~~any one of claims 1 to 5~~ claim 1, wherein the substance is a non-protein substance.

9. (Original) The pharmaceutical composition of claim 8, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

10. (Original) A pharmaceutical composition for preventing, treating, or prophylaxis of inflammation, comprising a substance having an activity in modulating signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.

11. (Original) The pharmaceutical composition of claim 10, wherein the substance has an activity in inhibiting proliferation of AILIM-expressing cells or in inhibiting production of a cytokine by AILIM-expressing cells.

12. (Original) The pharmaceutical composition of claim 11, wherein the cytokine is interferon γ which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

13. (Currently Amended) The pharmaceutical composition of ~~any one of claims 10 to 12~~ claim 10, wherein the inflammation is hepatitis.

14. (Currently Amended) The pharmaceutical composition of ~~any one of claims 10 to 13~~
claim 10, wherein the substance is a protein substance.

15. (Original) The pharmaceutical composition of claim 14, wherein the protein
substance is selected from the group consisting of:

- a) an antibody which binds to AILIM or a portion thereof;
- b) a polypeptide comprising the whole or a portion of an extracellular region of
AILIM;
- c) a fusion polypeptide comprising the whole or a portion of an extracellular region
of AILIM and the whole or a portion of a constant region of immunoglobulin heavy chain; and
- d) a polypeptide which binds to AILIM.

16. (Currently Amended) The pharmaceutical composition of ~~any one of claims 10 to 13~~
claim 10, wherein the substance is a non-protein substance.

17. (Original) The pharmaceutical composition of claim 16, wherein the non-protein
substance is DNA, RNA, or a chemically synthesized compound.

18. (Original) A pharmaceutical composition for preventing, treating, or prophylaxis of
graft versus host reaction and immune rejection accompanying graft versus host reaction or
transplantation of a tissue or organ, comprising a substance having an activity in modulating
signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.

19. (Original) The pharmaceutical composition of claim 18, wherein the substance has
an activity in inhibiting proliferation of AILIM-expressing cells or inhibiting production of a
cytokine by AILIM-expressing cells.

20. (Original) The pharmaceutical composition of claim 19, wherein the cytokine is interferon γ which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

21. (Currently Amended) The pharmaceutical composition of ~~any one of claims 18 to 20~~ claim 18, wherein the substance is a protein substance.

22. (Original) The pharmaceutical composition of claim 21, wherein the protein substance is selected from the group consisting of:

- a) an antibody which binds to AILIM or a portion thereof;
- b) a polypeptide comprising the whole or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising the whole or a portion of an extracellular region of AILIM and the whole or a portion of a constant region in immunoglobulin heavy chain; and
- d) a polypeptide which binds to AILIM.

23. (Currently Amended) The pharmaceutical composition of ~~any one of claims 18 to 20~~ claim 18, wherein the substance is a non-protein substance.

24. (Original) The pharmaceutical composition of claim 23, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.

25. (Original) A pharmaceutical composition for preventing immune response triggered by a foreign antigen or an autoantigen, comprising a substance having an activity of controlling signal transduction mediated by AILIM, and a pharmaceutically acceptable carrier.

26. (Original) The pharmaceutical composition of claim 25, wherein the immune response is production of an antibody against the antigen, cell proliferation, or production of a cytokine.

27. (Currently Amended) The pharmaceutical composition of claim 25 ~~or 26~~, wherein the substance has an activity in inhibiting proliferation of AILIM-expressing cells or in inhibiting production of a cytokine by AILIM-expressing cells.

28. (Original) The pharmaceutical composition of claim 27, wherein the cytokine is interferon γ which is a cytokine produced by Th1 type T cells, or interleukin 4 which is a cytokine produced by Th2 type T cells.

29. (Currently Amended) The pharmaceutical composition of ~~any one of claims 25 to 28~~ claim 25, wherein the substance is a protein substance.

30. (Original) The pharmaceutical composition of claim 29, wherein the protein substance is selected from the group consisting of:

- a) an antibody which binds to AILIM or a portion thereof;
- b) a polypeptide comprising the whole or a portion of an extracellular region of AILIM;
- c) a fusion polypeptide comprising the whole or a portion of an extracellular region of AILIM and the whole or a portion of a constant region of immunoglobulin heavy chain; and
- d) a polypeptide which binds to AILIM.

31. (Currently Amended) The pharmaceutical composition of ~~any one of claims 25 to 28~~ claim 25, wherein the substance is a non-protein substance.

Applicant : Katsunari Tezuka et al.
Serial No. :
Filed : Herewith
Page : 8 of 9

Attorney's Docket No.: 14539-005002 / JF-82US-C1

32. (Original) The pharmaceutical composition of claim 31, wherein the non-protein substance is DNA, RNA, or a chemically synthesized compound.